Biological Effects of Insulin and Its Analogs on Cancer Cells With Different Insulin Family Receptor Expression

Journal of Cellular Physiology

Volumn 229, Issue 11, 2014, Pages 1817-1821

  Sciacca, Laura ^a   Cassarino, Maria Francesca ^a   Genua, Marco ^a   Vigneri, Paolo ^a   Giovanna Pennisi, Maria ^a   Malandrino, Pasqualino ^a   Squatrito, Sebastiano ^a   Pezzino, Vincenzo ^a   Vigneri, Riccardo ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b Humanitas Oncology Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN DERIVATIVE; INSULIN RECEPTOR; SOMATOMEDIN C;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CANCER GROWTH; CELL INVASION; CELL PROLIFERATION; CELL STIMULATION; COLONY FORMATION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MITOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION;

CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; NEOPLASM INVASIVENESS; NEOPLASMS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN;

EID: 84904906540     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24635     Document Type: Article

References (31)

1. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. 2009. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586-623.
2. Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring HU. 1998. The long acting human insulin analog HOE 901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res 30:123-129.
3. Dideriksen LH, Jorgensin LN, Drejer K. 1992. Carcinogenic effect on female rats after 12 months administration of the insulin analog B10 Asp. Diabetes 41:143A.
4. Ebeling P, Tuominen JA, Koivisto VA. 1996. Insulin analogues and carcinoma of the breast. Diabetologia 39:124-125.
5. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R. 1999. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278-3288.
6. Giorgino F, Belfiore A, Milazzo G, Costantino A, Maddux B, Whittaker J, Goldfine ID, Vigneri R. 1991. Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. Mol Endocrinol 5:452-459.
7. Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, Klein HH, Lundemose AG. 1996. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315: 271-279.
8. Ish-Shalom D, Christoffersen CT, Vorwerk P, Sacerdoti-Sierra N, Shymko RM, Naor D, De Meyts P. 1997. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 40:S25-S31.
9. Janghorbani M, Dehghani M, Salehi-Marzijarani M. 2012. Systematic review and meta-analysis of insulin therapy and risk of cancer. Horm Cancer 3:137-146.
10. Kabat GC, Kim M, Caan BJ, Chlebowski RT, Gunter MJ, Ho GY, Rodriguez BL, Shikany JM, Strickler HD, Vitolins MZ, Rohan TE. 2009. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 125:2704-2710.
11. Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC, Conover CA. 2002. Functional insulin receptors on human epithelial ovarian carcinoma cells: Implications for IGF-II mitogenic signaling. Endocrinology 143:3259-3267.
12. Karlstad O, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, Andersen M, Auvinen A, Haukka J, Furu K, de Vries F, De Bruin ML. 2013. Use of insulin and insulin analogs and risk of cancer- - Systematic review and meta-analysis of observational studies. Curr Drug Saf 8:333-348.
13. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T. 2000. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005.
14. LeRoith D. 2010. Can endogenous hyperinsulinaemia explain the increased risk of cancer development and mortality in type 2 diabetes: Evidence from mouse models. Diabetes Metab Res Rev 26:599-601.
15. Liefvendahl E, Arnqvist HJ. 2008. Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res 40:369-374.
16. Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R. 1997. ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: Evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 18:19-25.
17. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine ID, Belfiore A. 1999. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 5:1935-1944.
18. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. 2002. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277:39684-39695.
19. Pisani P. 2008. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 114:63-70.
20. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, Sbraccia P, Goldfine ID, Vigneri R, Belfiore A. 1999. Insulin receptor activation by IGF-II in breast cancers: Evidence for a new autocrine/paracrine mechanism. Oncogene 18:2471-2479.
21. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R. 2010. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53:1743-1753.
22. Sciacca L, Vigneri R, Tumminia A, Frasca F, Squatrito S, Frittitta L, Vigneri P. 2013. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis 23:808-815.
23. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D. 2009. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429-441.
24. Sieg DJ, Ilic D, Jones KC, Damsky CH, Hunter T, Schlaepfer DD. 1998. Pyk2 and Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated signaling events but Pyk2 does not fully function to enhance FAK- cell migration. EMBO J 17:5933-5947.
25. Smith U, Gale EA. 2009. Does diabetes therapy influence the risk of cancer?. Diabetologia 52:1699-1708.
26. Sommerfeld MR, Muller G, Tschank G, Seipke G, Habermann P, Kurrle R, Tennagels N. 2010. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS ONE 5:e9540.
27. Vigneri P, Frasca F, Sciacca L, Frittitta L, Vigneri R. 2006. Obesity and cancer. Nutr Metab Cardiovasc Dis 16:1-7.
28. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. 2009. Diabetes and cancer. Endocr Relat Cancer 16:1103-1123.
29. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. 2009. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25:41-49.
30. Xue G, Hemmings BA. 2013. PKB/Akt-dependent regulation of cell motility. J Natl Cancer Inst 105:393-404.
31. Yehezkel E, Weinstein D, Simon M, Sarfstein R, Laron Z, Werner H. 2010. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor. Diabetologia 53:2667-2675.